| ToxCast database |
• 222 high-throughput
screening assays, including endpoints
related to cell cycle and morphology control, steroid hormone homeostasis,
DNA-binding proteins, and other protein families (e.g., kinases, cytochromes,
and transporters) |
ToxCast database version 3.324
|
| eMolTox database |
• 136 in vitro assays, including endpoints related to
mutagenicity, cytotoxicity, hormone homeostasis, neurotransmitters,
and several protein families (e.g., nuclear receptors, cytochromes,
and cell surface receptors) |
Ji et al.25
|
| genotoxicity |
• AMES mutagenicity assay |
AMES assay: eChemPortal,26 Benigni et
al.,28 Hansen et al.29
|
| • chromosome aberration
(CA) assay |
| • mammalian mutagenicity
(MM) assay |
CA and MM assays: eChemPortal, Benigni et
al. |
| bioavailability |
•
human oral bioavailability assay |
Falcón-Cano
et al.27
|
| permeability |
• Caco-2 assay |
Wang et al.30
|
| thyroid
hormone homeostasis |
• deiodinases 1, 2, and 3
inhibition assays |
Garcia de Lomana et al.31
|
| • thyroid peroxidase
inhibition assay |
| • sodium iodide symporter
inhibition assay |
| • thyroid hormone
receptor antagonism assay |
| • thyrotropin-releasing
hormone receptor antagonism
assay |
| • thyroid stimulating hormone
receptor agonism and antagonism
assays |
| P-glycoprotein inhibition |
• P-glycoprotein (ABCB1) inhibition assay |
Broccatelli
et al.32
|
